The document is a rating report from Credit Analysis & Research Ltd. that reaffirms credit ratings for Biostadt India Limited.
Some key points:
- The ratings consider BIL's experienced management, product diversity, and comfortable capital structure, but are limited by its moderate scale of operations and low profit margins in the agrochemicals industry.
- BIL manufactures agrochemicals and acquired a seeds company to expand in that segment.
- The ability to improve scale and profitability will be key factors for further rating changes.
The document is a rating report from Credit Analysis & Research Ltd. that reaffirms credit ratings for Biostadt India Limited.
Some key points:
- The ratings consider BIL's experienced management, product diversity, and comfortable capital structure, but are limited by its moderate scale of operations and low profit margins in the agrochemicals industry.
- BIL manufactures agrochemicals and acquired a seeds company to expand in that segment.
- The ability to improve scale and profitability will be key factors for further rating changes.
The document is a rating report from Credit Analysis & Research Ltd. that reaffirms credit ratings for Biostadt India Limited.
Some key points:
- The ratings consider BIL's experienced management, product diversity, and comfortable capital structure, but are limited by its moderate scale of operations and low profit margins in the agrochemicals industry.
- BIL manufactures agrochemicals and acquired a seeds company to expand in that segment.
- The ability to improve scale and profitability will be key factors for further rating changes.
November 12, 2013 CARE REAFFIRMS THE RATINGS ASSIGNED TO THE BANK FACILITIES OF BIOSTADT INDIA LIMITED Rating Facilities/Instruments Amount (Rs. crore) Ratings 1 Remarks Long-term/Short-term WC limits (fund-based/non-fund based) 65 CARE BBB+/CARE A2 ( Triple B Plus/ A Two) Reaffirmed Total 65
Rating Rationale The ratings derive strength from the experienced management and established presence of Biostadt India Ltd (BIL) in the biological segment within the agrochemicals industry, diversified product profile, comfortable capital structure and the debt service coverage indicators. However, the ratings are constrained by the comparatively moderate size of operations and low profitability margins within the agrochemicals industry, the working-capital intensive nature of operations arising out of the seasonality of its business and the highly competitive and fragmented nature of the agrochemical industry. The ability of BIL to improve its scale of operations and profitability margins are the main rating sensitivities.
Background Biostadt India Ltd (BIL) is mainly involved in the manufacturing and marketing of agrochemicals. BIL was set up as a division of Wockhardt Ltd, in 1986 to mark Wockhardt Group's foray into the agriculture segment in India. In 2003, the division was demerged from Wockhardt Ltd, and was established as an independent entity under the leadership of Mr J S Khorakiwala (Chairman & Managing Director). The company is headquartered in Mumbai and has three manufacturing units located in Aurangabad, Silvassa and Jammu. The major products manufactured by the company are biologicals under the brand name Biozyme (used for increasing the yield and quality of various crops); crop protection chemicals; hybrid seeds and aqua culture range of products. During H1FY14, BIL acquired 100% stake in New Nandi Seed Corporation (a partnership firm, in the process of getting incorporated as a private limited company) based in Gujarat by investing Rs.10 crores in the equity and preference share capital of the company. This acquisition is expected to enhance the position of BIL in the seeds segment. During FY13 (refers to the period April 1 to March 31), BIL had recorded a PAT of Rs.14.77 crore (PY Rs.12.30 crore) on a total income of Rs.336.30 crore (PY Rs.311.36 crore). Besides, during Q1FY14 (un-audited financials), the company had reported an income of Rs.98.97 crore and PAT of Rs.8.20 crore.
Analyst Contact Name: Arunava Paul Tel # 6754 3667 Email: arunava.paul@careratings.com
1 Complete definition of the ratings assigned are available at www.careratings.com and other CARE publications
Brief Rationale
Credit Analysis & Research Ltd., 4 th Floor, Godrej Coliseum, Somaiya Hospital Road Sion East, Mumbai 400 022. INDIA Tel # 022 6754 3456 Fax # 6754 3457
CARE has classified instruments rated by it on the basis of complexity. This classification is available at www.careratings.com. Investors/market intermediaries/regulators or others are welcome to write to care@careratings.com for any clarifications.
DISCLAIMER CAREs ratings are opinions on credit quality and are not recommendations to sanction, renew, disburse or recall the concerned bank facilities or to buy, sell or hold any security. CARE has based its ratings on information obtained from sources believed by it to be accurate and reliable. CARE does not, however, guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. Most entities whose bank facilities/instruments are rated by CARE have paid a credit rating fee, based on the amount and type of bank facilities/instruments.
Brief Rationale
Credit Analysis & Research Ltd., 4 th Floor, Godrej Coliseum, Somaiya Hospital Road Sion East, Mumbai 400 022. INDIA Tel # 022 6754 3456 Fax # 6754 3457
CARE is headquartered in Mumbai, with Offices all over India. The office addresses and contact numbers are given below: HEAD OFFICE: MUMBAI
Mr. D.R. Dogra Managing Director Mobile : +91-98204 16002 E-mail : dr.dogra@careratings.com Mr. Rajesh Mokashi Dy. Managing Director Mobile +91-98204 16001 E-mail: rajesh.mokashi@careratings.com
Ms. Meenal Sikchi Vice President Bank Loan & Instrument Rating Mobile: +91-9819009839 mail: meenal.sikchi@careratings.com